Clinical trials: TDP-43 Proteinopathies
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.
- Trial name
- NCT07093268
- Testing
- Intrathecal Riluzole
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Brain Trust Bio
Amyotrophic Lateral Sclerosis
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04326283
- Testing
- Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- Genuv Inc.
Frontotemporal Dementia, Pick Complex
A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia
The purpose of this study is to explore the safety and tolerability and the efficacy of galantamine treatment in subjects with Pick Complex/ Frontotemporal Dementia (PC/FTD).
- Trial name
- NCT00416169
- Testing
- galantamine hydrobromide
- Volunteers
- 41 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are…
- Trial name
- NCT03280056
- Testing
- NurOwn® (MSC-NTF cells), Bone Marrow aspiration
- Where
- 6 sites in United States
- Volunteers
- 196 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
The study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal derived neural stem cell transplantation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01730716
- Testing
- Human spinal cord stem cell implantation
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuralstem Inc.
ALS (Amyotrophic Lateral Sclerosis)
Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04090684
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Amyotrophic Lateral Sclerosis
Phase 3 Extension Study of Dexpramipexole in ALS
The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
- Trial name
- ENVISION (NCT01622088)
- Testing
- Dexpramipexole
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 616 people
- Sponsor
- Knopp Biosciences
ALS, Amyotrophic Lateral Sclerosis
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study.
- Trial name
- NCT04948645
- Testing
- Fosigotifator
- Where
- 14 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- AbbVie
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Amyotrophic Lateral Sclerosis
An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS
The goal of this clinical trial is to evaluate the safety and efficacy of a single intrathecal injection of RJK002 in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06454682
- Testing
- RJK002 Intrathecal injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- RJK Biopharma Ltd
Amyotrophic Lateral Sclerosis
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.
- Trial name
- NCT01089010
- Testing
- 250 mg CK-2017357, 500 mg CK-2017357
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the…
- Trial name
- NCT04993755
- Testing
- TPN-101, 400 mg/day
- Where
- 19 sites in United States, Belgium and 3 more
- Volunteers
- 42 people
- Sponsor
- Transposon Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
- Trial name
- ADOREXT (NCT05866926)
- Testing
- FAB122
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Ferrer Internacional S.A.
ALS, Amyotrophic Lateral Sclerosis
Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients
Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way.
- Trial name
- NCT05423678
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Healthy Volunteers
A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects
To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant.
- Trial name
- NCT03954600
- Testing
- NPT520-34 (125 mg)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Neuropore Therapies Inc.
Amyotrophic Lateral Sclerosis (ALS)
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT07118319
- Testing
- Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Tetraplegia/Tetraparesis, Quadriplegia
VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration
The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- NCT07224256
- Testing
- N1 Implant, R1 Robot
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Neuralink Corp
Neurologic Disorder, Neurologic Diseases
Functional Outcomes and Control Using Synchron BCI - Australia
Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)
- Conditions
- Neurologic Disorder, Neurologic Diseases, MND (Motor Neurone DIsease), Motor Neuron Disease
- Trial name
- FOCUS-AUS (NCT07533903)
- Testing
- Stentrode
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Amyotrophic Lateral Sclerosis
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
- Trial name
- CARDINALS (NCT05349721)
- Testing
- PTC857
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 336 people
- Sponsor
- PTC Therapeutics